Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

This study is a single-arm prospective cohort study designed to evaluate the efficacy and safety of triple therapy (ADT + darolutamide + docetaxel) combined with transrectal high-intensity focused ultrasound (HIFU) focal therapy in patients with high-tumor-burden metastatic hormone-sensitive prostate cancer (mHSPC). A total of 116 high-tumor-burden mHSPC patients will be enrolled and are scheduled to receive the following treatment: Darolutamide + Docetaxel + ADT + Transrectal HIFU Focal Therapy for the Prostate.

Trial Details

NCT ID
NCT07172685
Phase
NA
Sponsor
Qilu Hospital of Shandong University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Patients who agree to participate in the study and sign the informed consent form.
  • Age ≥18 years, male.
  • Histologically or cytologically confirmed prostate adenocarcinoma.
  • Bone scan, CT, or MRI showing ≥4 bone metastases (with ≥1 outside the pelvis or spine) or visceral metastases.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →